Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 99 of 173 for:    pertuzumab

The Use of FES-PET Imaging as a Tool to Detect a Possible Reversion of Estrogen Receptor (ER)-α Status in Patients With Metastatic Breast Cancer HER2 + and ERα Neg Treated With Trastuzumab + Pertuzumab + Taxane. (REVER)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03619044
Recruitment Status : Recruiting
First Posted : August 7, 2018
Last Update Posted : December 4, 2019
Sponsor:
Information provided by (Responsible Party):
Institut Claudius Regaud

No Study Results Posted on ClinicalTrials.gov for this Study
Recruitment Status : Recruiting
Estimated Primary Completion Date : November 2020
Estimated Study Completion Date : December 2020